Guoliang Zhang

This inventor holds 23 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Cancer Therapeutics. Top assignees: Beigene, Ltd., Beone Medicines I Gmbh, Microsoft Technology Licensing, LLC. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guoliang Zhang. Retrieved from https://idiyas.com/inventor/guoliang-zhang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 11)

% Patents Active = 95.7

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 26)

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 39(Granted Patents)

Company Filing History:

Beone Medicines I Gmbh

patents

2 out of 56,259

Microsoft Technology Licensing, LLC

patents

4. 1 out of 22

Beigene Switzerland Gmbh

patents

5. 1 out of 4

Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.

patents

6. 1 out of 5

Beone Medicines | Gmbh

patents

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

KRAS Inhibitors

TLR Agonists

RAF Kinase

Cancer Treatment

Imidazo Compounds

Tricyclic Compounds

Pyrazolotriazolopyrimidine

Heterocyclic Compounds

PD-1 Antagonist

Indoleamine Inhibitors

Solid Dispersion

Text to Speech

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679844 - Imidazotriazine and pyrrolopyrimidine derivatives as KRAS G12C inhibitors (2026-07-14),

2. 12637480 - Heterocyclic compounds as sting modulators (2026-05-26),

3. 12612407 - Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist (2026-04-28),

4. 12590096 - Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists (2026-03-31),

5. 12582604 - Stable solid dispersion of a B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor (2026-03-24),

6. 12576099 - Ribose-modified cap analog and use thereof (2026-03-17),

7. 12281119 - Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist (2025-04-21),

8. 11534431 - Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer (2022-12-27),

9. 11472811 - Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist (2022-10-18),

10. 10882856 - 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases (2021-01-05),

11. 10864203 - Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer (2020-12-15),

12. 10647714 - 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases (2020-05-12),

13. 10576087 - Fused tricyclic compounds as Raf kinase inhibitors (2020-03-03),

14. 10562899 - Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors (2020-02-18),

15. 10351559 - Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore (2019-07-16),

Sure, I can help you with that!

Title: The Innovator: Guoliang Zhang's Journey of Transformative Inventions

Introduction: Guoliang Zhang, a prolific inventor based in Beijing, China, has made his mark in the field of oncology with a series of groundbreaking patents.

Latest Patents: Zhang's recent patents showcase his dedication to advancing cancer treatment. He introduced a pharmaceutical combination involving a PD-1 antagonist and a RAF inhibitor, demonstrating synergistic efficacy in combating cancer. Additionally, he unveiled pyrazolotriazolopyrimidine derivatives as effective A2A receptor antagonists for treating cancer.

Career Highlights: With an impressive portfolio of 16 patents, Guoliang Zhang has left an indelible impact on the industry. Notably, he has contributed significantly to Beigene Ltd. and Microsoft Technology Licensing, LLC, where his innovative spirit flourished.

Collaborations: Zhang's success is also attributed to his fruitful collaborations with esteemed colleagues such as Changyou Zhou and Shaohui Wang. Together, they have pushed the boundaries of medical science and drug development.

Conclusion: Guoliang Zhang's inventive prowess and unwavering commitment to revolutionize cancer treatment have solidified his position as a pioneering figure in the realm of oncology. His relentless pursuit of innovation continues to inspire and shape the future of healthcare.

Profile summary based on public USPTO records.